KRAS Mutations: Codons 12, 13 and 61

Specimen Collection, Storage, and Shipping

Test Information:

Activating somatic mutations of KRAS are present in approximately 20-30% of human malignancies, including 30-50% of colorectal cancers and 30% of adenocarcinomas of the lung. The mutation status of KRAS and other oncogenic drivers, combined with clinical features, help guide tumor therapy. For example, per the National Comprehensive Cancer Network guidelines, colon cancer patients with known KRAS or NRAS mutations or primary right-sided colon cancers should not be treated with cetuximab or panitumumab. BRAF V600E is also likely to predict unresponsiveness. In non-small cell lung cancers, KRAS mutation is associated with primary anti-EGFR therapy resistance, and KRAS sequencing may identify patients more likely to have EGFR mutations. This assay detects down to 5% mutations of codons 12 and 13 in exon 2 and codon 61 in exon 3 of KRAS, using PCR and pyrosequencing.

Requisition Code:

KRAS mutations (codons 12, 13, and 61)

CPT Codes:

81275; 81276; G0452-26 (x2) (add G88381 if manual dissection is needed)

Turn Around Time:

7-10 days

Specimen Requirements:

Decalcified specimens are not accepted.

Paraffin Block

Collect:           Formalin-fixed, paraffin embedded tissues

Storage:         Room temperature

Remarks:       Submit the paraffin block, 1 H&E with marked location of most abundant tumor (or photocopy of marked H&E) and an approximate % of tumor cells in the area and a copy of the Surgical Pathology report.

Transport:      See Standard Shipping Procedures

References:
  1. Comprehensive Cancer Network. Colon Cancer (Version 1.2017). http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed Dec 14, 2016.
  2. Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 3.2017). http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed Dec 14, 2016.